Molecule News and Research

RSS

Good cholesterol efficiency more important than quantity: Study

According to a new study the amount of good cholesterol a person has is not as important as how well that good cholesterol works to stop heart disease. Good cholesterol or High-Density Lipoprotein—also known as HDL is known to be healthy for the heart with people having high blood levels of HDL being at a lower risk of developing heart disease than people with low levels.

13 Jan 2011

Scientists demonstrate how one gene evolves two competing functions via duplication

Researchers report that they are the first to show in molecular detail how one gene evolved two competing functions that eventually split up - via gene duplication - to pursue their separate destinies.

13 Jan 2011

Genetic information from Guthrie cards may serve as valuable resource to diagnose infant diseases

Van Andel Research Institute researchers have developed a method that can yield more information from archived newborn blood that has implications for a vast array of research, including population health studies and answering questions about diseases in infants and children.

13 Jan 2011

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

VistaGen Therapeutics, Inc. and NuPotential, Inc. today announced that the National Heart, Lung and Blood Institute of the U.S. National Institutes of Health (NIH) has awarded to the companies a grant of approximately $500,000 to accelerate development of novel and safer approaches to generate patient-specific induced pluripotent stem (iPS) cells for regenerative medicine, drug discovery and drug rescue.

13 Jan 2011

Study indicates disease's underlying causes in mice, finds compounds that normalize Alzheimer's brain

A Blanchette Rockefeller Neurosciences Institute study published today in the Journal of Neuroscience reveals underlying causes for the degeneration of synapses in Alzheimer's Disease and identifies promising pharmaceutical solutions for the devastating condition that affects more than 5 million people in the United States.

12 Jan 2011

US most susceptible to brand erosion post patent expiry

On average, small molecule brands in the US experienced the greatest degree of brand erosion following patent expiry and exposure to direct generic competition, according to a new report from independent market analyst, Datamonitor.

12 Jan 2011

Offensive protein generated by HPV handicaps defensive protein made by the human body

An international team of researchers is reporting that it has uncovered new information about human papillomavirus that one day may aid in the development of drugs to eliminate the cervical-cancer-causing infection.

12 Jan 2011

Study reveals underlying causes for degeneration of synapses in Alzheimer's Disease

A Blanchette Rockefeller Neurosciences Institute (BRNI) study published today in the Journal of Neuroscience reveals underlying causes for the degeneration of synapses in Alzheimer's Disease and identifies promising pharmaceutical solutions for the devastating condition that affects more than 5 million people in the United States.

12 Jan 2011

Eli Lilly, Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Boehringer Ingelheim and Eli Lilly and Company today announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.

12 Jan 2011

SciClone initiates phase 2b study of SCV-O7 for oral mucositis

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced the enrollment of the first patient in the company's phase 2b clinical trial of SCV-07 for the prevention of oral mucositis (OM) -- a painful, debilitating, and costly toxicity caused by chemoradiotherapy regimens used to treat head and neck cancer.

11 Jan 2011

Lilly and Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Eli Lilly and Company and Boehringer Ingelheim today announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development.

11 Jan 2011

Mechanism for binding oxygen to metalloporphyrins seen on a molecular level

The mechanism for binding oxygen to metalloporphyrins is a vital process for oxygen-breathing organisms. Understanding how small gas molecules are chemically bound to the metal complex is also important in catalysis or the implementation of chemical sensors. When investigating these binding mechanisms, scientists use porphyrin rings with a central cobalt or iron atom. They coat a copper or silver support surface with these substances.

11 Jan 2011

Research could lead to new approaches to treat dementia

A researcher at the University of Pittsburgh School of Medicine, in collaboration with scientists from the National Institutes of Health, has discovered that the deadly plaques of Alzheimer's disease interact with certain cellular proteins to inhibit normal signals that maintain blood flow to the brain.

11 Jan 2011

GSK, Epizyme enter partnership to discover, develop, and market epigenetic therapeutics

Epizyme today announced a worldwide strategic alliance with GlaxoSmithKline to discover, develop, and market novel small molecule therapeutics targeting histone methyltransferases, an important class of epigenetic enzymes, for the treatment of cancer and other diseases.

11 Jan 2011

New insights into estrogen receptor beta

Research with significant implications in the treatment and intervention of cancer and obesity has been published recently in two prestigious journals by University of Houston (UH) biochemist Dr. Jan--ke Gustafsson.

11 Jan 2011

PPD announces joint venture with TBL to develop novel biotherapeutics

PPD, today announced it has established a joint venture with Taijitu Biologics Limited in the area of the discovery of novel biotherapeutics. The joint venture, named BioDuro Biologics, expands PPD's capability to deliver unique, highly differentiated drug discovery services for biopharmaceutical companies across the globe.

10 Jan 2011

New study finds extending term of exclusive access can lead to higher drug costs in short term

A new study in the January 2011 issue of Health Affairs is the first to calculate the financial and social costs of limiting access to trial data — and finds that extending the term of exclusive access will lead to higher drug costs in the short term but also to more than 200 extra drug approvals and to greater life expectancy in the next several decades.

10 Jan 2011

UCB, Emerald BioStructures expand collaboration for structure-based drug discovery

Emerald BioStructures, a leading provider of fragment-based drug discovery services, announced today that it has successfully achieved the second milestone in its collaboration with UCB on the structure-based discovery of small molecule modulators of undisclosed targets.

10 Jan 2011

U-M lab ranks No. 1 in protein structure and function prediction in scientific competition

The University of Michigan Health System took top honors in the Critical Assessment of Techniques for Protein Structure Prediction, a biennial scientific competition to test protein structure and function prediction methods developed by laboratories all over the world.

10 Jan 2011

Infinity provides guidance on anticipated pipeline and business goals for 2011

Infinity Pharmaceuticals, Inc. today provided guidance on its anticipated pipeline and business goals for 2011. Infinity begins the year with a broad pipeline of four drug candidates in clinical development and a fifth expected to enter the clinic during the year. The company also enters 2011 with approximately $345 million in committed capital.

7 Jan 2011

Molecule News and Research

Good cholesterol efficiency more important than quantity: Study

Scientists demonstrate how one gene evolves two competing functions via duplication

Genetic information from Guthrie cards may serve as valuable resource to diagnose infant diseases

NIH awards VistaGen and NuPotential $500,000 grant to advance iPS stem cell technology

Study indicates disease's underlying causes in mice, finds compounds that normalize Alzheimer's brain

US most susceptible to brand erosion post patent expiry

Offensive protein generated by HPV handicaps defensive protein made by the human body

Study reveals underlying causes for degeneration of synapses in Alzheimer's Disease

Eli Lilly, Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

SciClone initiates phase 2b study of SCV-O7 for oral mucositis

Lilly and Boehringer Ingelheim enter global agreement to develop and commercialize diabetes compounds

Mechanism for binding oxygen to metalloporphyrins seen on a molecular level

Research could lead to new approaches to treat dementia

GSK, Epizyme enter partnership to discover, develop, and market epigenetic therapeutics

New insights into estrogen receptor beta

PPD announces joint venture with TBL to develop novel biotherapeutics

New study finds extending term of exclusive access can lead to higher drug costs in short term

UCB, Emerald BioStructures expand collaboration for structure-based drug discovery

U-M lab ranks No. 1 in protein structure and function prediction in scientific competition

Infinity provides guidance on anticipated pipeline and business goals for 2011

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News